Literature DB >> 7140004

The protein binding and elimination of methotrexate after intravenous infusions in cancer patients.

J W Paxton.   

Abstract

1. Total serum concentrations and protein binding of methotrexate (MTX) have been studied after fifty-eight 6 h MTX infusions in nineteen cancer patients. 2. There was a linear relationship between dose (mg/kg) and serum MTX concentration at termination of infusion. 3. The elimination of total serum and "free' MTX followed similar bi-exponential expressions during the 72 h studied after the infusion. 4. Of the eight occasions when total serum concentrations did not fall below 10(-7) mol/l on the third day, five were associated with toxicity. 5. Mean per cent MTX bound by sera from the nineteen patients was 47.2 (s.d. = 4.4) per cent and appeared to be independent of MTX concentration within the range studied. 6. This study suggests that the very high binding previously reported for MTX should be questioned and that measurement of total serum MTX concentration (bound plus free) is sufficient for the recognition of patients who might be at risk of developing toxicity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7140004     DOI: 10.1111/j.1440-1681.1982.tb00800.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  4 in total

1.  Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma.

Authors:  D J Grimes; M R Bowles; J A Buttsworth; D B Thomson; P J Ravenscroft; P F Nixon; R F Whiting; S M Pond
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

2.  Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.

Authors:  Isabelle Benz-de Bretagne; Noël Zahr; Amélie Le Gouge; Jean-Sébastien Hulot; Caroline Houillier; Khe Hoang-Xuan; Emmanuel Gyan; Séverine Lissandre; Sylvain Choquet; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

3.  Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma.

Authors:  T Pignon; B Lacarelle; F Duffaud; P Guillet; J Catalin; A Durand; S Monjanel; R Favre
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Pharmacokinetics of different doses of methotrexate at steady state by in situ microdialysis in a rat model.

Authors:  P O Ekstrøm; A Anderson; D J Warren; K E Giercksky; L Slørdal
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.